Table 2.
Main studies evaluating clinical and pathologic characteristics of patients with NET G−3.
Study, Year | Number of Patients | Median of Age (Years) | Tumor Sites | Metastatic State (%) | Median Ki−67 (%) | Median Survival (Months) |
---|---|---|---|---|---|---|
Velayoudom-Céphise et al. [3], 2013 | 12 | 56 | Pancreas, non-digestive sites | 100 | 21 | 41 |
Heetfeld et al. [12], 2015 | 37 | 52 | Pancreas, rectum, stomach, small bowel | 62 | 30 | 99 |
Basturk et al. [2], 2015 | 19 | 54 | Pancreas | 67 | 40 | 54 |
Scoazec et al. [32], 2017 | 21 | NA | Pancreas, colorectal, stomach, small bowel | NA | 35 | NA |
Hijioka et al. [13], 2017 | 21 | 63 | Pancreas | 71 | 29 | 42 |
NA: non-available.